The successful IHC immunolabeling of α-, β-, and γ-SGs in this study indicates that alterations in the expression of α-, β-, or γ-SGs can be used to clarify the MD type in cases where the clinical diagnosis of LGMD2D, LGMD2E, or LGMD2C is unclear. This evidence concerns the gene SGCG and autosomal recessive limb-girdle muscular dystrophy type 2E.